Treatment of schizophrenia: Focus on roluperidone

M. L. Miller, P. D. Harvey

Research output: Contribution to journalArticlepeer-review


This article describes the development of roluperidone, a serotonin and sigma receptor agent that is being developed for the treatment of negative symptoms of schizophrenia. As we describe below, there are no treatments currently approved for negative symptoms in schizophrenia and this has been an area of considerable interest in terms of drug development. We will describe academic and regulatory perspectives on the definition of negative symptoms, assessments for negative symptoms and morbidity associated with negative symptoms. Further, we will examine some previous efforts to treat negative symptoms and the possible reasons for their lack of success. Lastly, we will discuss results of preliminary studies investigating roluperidone as a possible treatment for negative symptoms and impaired cognition in patients with schizophrenia.

Original languageEnglish (US)
Pages (from-to)893-902
Number of pages10
JournalDrugs of the Future
Issue number12
StatePublished - Dec 2020


  • 5-HT receptor antagonists
  • MIN-101
  • Negative symptoms
  • Roluperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Treatment of schizophrenia: Focus on roluperidone'. Together they form a unique fingerprint.

Cite this